scholarly journals Is intravenous contrast necessary for detection of clinically significant extracolonic findings in patients undergoing CT colonography?

2014 ◽  
Vol 87 (1036) ◽  
pp. 20130667 ◽  
Author(s):  
T Y Yau ◽  
LAA Alkandari ◽  
B Haaland ◽  
W Low ◽  
C H Tan
Author(s):  
Gerard Lambe ◽  
Peter Hughes ◽  
Louise Rice ◽  
Caoimhe McDonnell ◽  
Mark Murphy ◽  
...  

AbstractCT colonography has emerged as the investigation of choice for suspected colorectal cancer in patients when a colonoscopy in incomplete, is deemed high risk or is declined because of patient preference. Unlike a traditional colonoscopy, it frequently reveals extracolonic as well as colonic findings. Our study aimed to determine the prevalence, characteristics and potential significance of extracolonic findings on CT colonography within our own institution. A retrospective review was performed of 502 patients who underwent CT colonography in our institution between January 1, 2010 and January 4, 2015. Of 502 patients, 60.63% had at least one extracolonic finding. This was close to other similar-sized studies (Kumar et al. Radiology 236(2):519–526, 2005). However, our rate of E4 findings was significantly higher than that reported in larger studies at 5.3%(Pooler et al. AJR 206:313–318, 2016). The difference may be explained by our combination of symptomatic/screening patients or by the age and gender distribution of our population. Our study lends support to the hypothesis that CT colonography may be particularly useful in identifying clinically significant extracolonic findings in symptomatic patients. CT colonography may allow early identification of extracolonic malignancies and life-threatening conditions such as an abdominal aortic aneurysm at a preclinical stage when they are amenable to medical or surgical intervention. However, extracolonic findings may also result in unnecessary investigations for subsequently benign findings.


2003 ◽  
Vol 124 (4) ◽  
pp. 911-916 ◽  
Author(s):  
Thomas M. Gluecker ◽  
C.Daniel Johnson ◽  
Lynn A. Wilson ◽  
Robert L. MacCarty ◽  
Timothy J. Welch ◽  
...  

Author(s):  
Stefaan Gryspeerdt ◽  
Philippe Lefere

2011 ◽  
Vol 55 (2) ◽  
pp. 149-152 ◽  
Author(s):  
Tom Sutherland ◽  
Elizabeth Coyle ◽  
Belinda Lui ◽  
Wai-Kit Lee

2003 ◽  
Vol 124 (4) ◽  
pp. A114 ◽  
Author(s):  
Amy Hara ◽  
Jonathan A. Leighton ◽  
Virender Sharma ◽  
Russell I. Heigh

2004 ◽  
Vol 38 (9) ◽  
pp. 767-771 ◽  
Author(s):  
Roshini C Rajapaksa ◽  
Michael Macari ◽  
Edmund J Bini

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 52-52
Author(s):  
Sasha C. Druskin ◽  
Jeffrey J. Tosoian ◽  
Allen Young ◽  
Kamyar Ghabili ◽  
Darian Andreas ◽  
...  

52 Background: PIRADS version 2 guidelines for the interpretation of multi-parametric prostate MRI (mpMRI) stipulates that dynamic contrast-enhanced (DCE) imaging be used to classify diffusion weighted imaging (DWI) score 3 peripheral zone lesions into PIRADS-3 (DCE-) or PIRADS-4 (DCE+) lesions. Despite this, it is unknown if DCE based classification separates lesions into clinically meaningful pathologic groups. Because use of contrast adds time, risk (though modest), and cost to mpMRI, we sought to examine whether use of DCE indeed improves detection of clinically-significant cancer. Methods: Using the Johns Hopkins MRI-ultrasound fusion prostate biopsy database and including only patients without a prior diagnosis of prostate cancer (n = 232), we identified patients with peripheral zone DWI-3 or DWI-4 lesions who underwent targeted biopsy of those lesions. Each lesion meeting the MRI criteria was considered separately, and grouped into one of three lesion MRI classifications – DWI-3/DCE-/PIRADS-3, DWI-3/DCE+/PIRADS-4, or DWI-4/PIRADS-4. The rates of benign, grade group (GG) 1, and GG ≥ 2 pathology were compared between the MRI classification groups. Results: One hundred forty-eight peripheral zone DWI-3 or DWI-4 lesions from a total of 106 patients were identified. The rate of benign(%)/GG1(%)/GG ≥ 2(%) biopsy pathology in the groups DWI-3/DCE-/PIRADS-3 (61 lesions), DWI-3/DCE+/PIRADS-4 (37 lesion), and DWI-4/PIRADS-4 (47 lesions) was 68.9/18.0/8.2, 59.5/13.5/18.9, and 44.7/23.4/27.7, respectively (P > 0.05 for the difference in rates of GG ≥ 2 pathology between the two PIRADS-4 groups and the two DWI-3 groups). Conclusions: Given the cost and morbidity of using intravenous contrast agents in prostate MRI, their clinical utility must be determined. In this study, DWI-3 peripheral zone lesions with DCE positivity appear to have a higher rate of clinically-significant (GG ≥ 2) cancer on biopsy. This study supports the use of DCE to better classify DWI-3 peripheral zone lesions however further study with expanded cohorts is indicated.


Sign in / Sign up

Export Citation Format

Share Document